Liraglutide oral GLP-1 weight loss drug approved for sale in the United States, has applied for listing in China.

On April 1st local time, Lilly announced that its oral small molecule GLP-1 receptor agonist orforglipron has been approved by the US FDA for the treatment of adult obesity or overweight, making it the second oral GLP-1 weight loss drug to be marketed globally. Lilly's orforglipron has also submitted applications for weight loss or blood sugar reduction in over 40 countries worldwide. At the end of last year, this drug also submitted an application for marketing approval in China for the treatment of type 2 diabetes and obesity.